SH3PXD2B sirna

SH3PXD2B siRNA (Mouse)

Cat. Num. AAA8215367

• Gene Names: Sh3pxd2b; TSK4; fad49; G431001E03Rik
• Reactivity: Mouse
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: SH3PXD2B; SH3PXD2B siRNA (Mouse); FAD49; TKS4; SH3 and PX domain-containing protein 2B; Factor for adipocyte differentiation 49; Tyrosine kinase substrate with four SH3 domains; SH3PXD2B sirna

• Host: Synthetic
• Reactivity: Mouse
• Specificity: SH3PXD2B siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 908

• Applicable Applications for SH3PXD2B sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse SH3PXD2B gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for SH3PXD2B sirna

siRNA to inhibit SH3PXD2B expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 63055065
• NCBI GeneID: 268396
• NCBI Accession #: NP_796338.2
• NCBI GenBank Nucleotide #: NM_177364.3
• UniProt Accession #: A2AAY5; Q1LZL8; Q1LZM5; Q3TB89; Q8BIC6; B6F0V1
• Molecular Weight: 101,517 Da
• NCBI Official Full Name: SH3 and PX domain-containing protein 2B
• NCBI Official Synonym Full Names: SH3 and PX domains 2B
• NCBI Official Symbol: Sh3pxd2b
• NCBI Official Synonym Symbols: TSK4; fad49; G431001E03Rik
• NCBI Protein Information: SH3 and PX domain-containing protein 2B
• UniProt Protein Name: SH3 and PX domain-containing protein 2B
• Protein Family: SH3 and PX domain-containing protein
• UniProt Gene Name: Sh3pxd2b
• UniProt Synonym Gene Names: Fad49; Tks4
• UniProt Entry Name: SPD2B_MOUSE

Uniprot Description

SH3PXD2B: Adapter protein involved in invadopodia and podosome formation and extracellular matrix degradation. Binds matrix metalloproteinases (ADAMs), NADPH oxidases (NOXs) and phosphoinositides. Acts as an organizer protein that allows NOX1- or NOX3-dependent reactive oxygen species (ROS) generation and ROS localization. Plays a role in mitotic clonal expansion during the immediate early stage of adipocyte differentiation. Defects in SH3PXD2B are the cause of Frank-Ter Haar syndrome (FTHS). It is a syndrome characterized by brachycephaly, wide fontanels, prominent forehead, hypertelorism, prominent eyes, macrocornea with or without glaucoma, full cheeks, small chin, bowing of the long bones and flexion deformity of the fingers. Belongs to the SH3PXD2 family.

Protein type: Lipid-binding

Cellular Component: cell projection; cytoplasm; podosome; cell junction

Molecular Function: phosphatidylinositol-5-phosphate binding; SH2 domain binding; phosphoinositide binding; phosphatidylinositol 3-phosphate binding

Biological Process: extracellular matrix disassembly; eye development; heart development; superoxide metabolic process; positive regulation of fat cell differentiation; cell differentiation; skeletal development